Healthy Skepticism Library item: 17217
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
HealthLeaders-InterStudy Offers Healthcare Analytics Tool to Help Pharmaceutical Companies Pinpoint Areas of Greatest Unmet Need
Pharma Live 2010 Feb 9
http://pharmalive.com/news/index.cfm?articleID=683773
Abstract:
PatientFinder Assesses the Number of Untreated, Insured Patients with a Specific Disease in a Specific Territory
Full text:
HealthLeaders-InterStudy, a leading provider of managed care market intelligence, today announced the company is now offering PatientFinder, a healthcare analytics tool that assesses local markets for pharmaceutical company expansion opportunity by determining the number of insured patients in a territory who have a specific disease but are untreated. This type of information is invaluable to pharmaceutical and clinical trial research companies who are challenged to pinpoint the areas of greatest need for their drugs.
“PatientFinder is an ideal tool to help pharmaceutical companies identify the territories that will yield the greatest business gain,” said Michael Malecki, Ph.D., product director, PatientFinder. “By providing an analysis of treatment rates against local insurance and pharmacy benefit coverage, PatientFinder demonstrates areas of true expansion potential that is vital to sales force alignment and growth.”
About PatientFinder
PatientFinder covers each of the 50 U.S. states and 317 U.S. metropolitan statistical areas (MSAs) and provides:
— Disease-specific prevalence numbers for each U.S. state and MSA. — Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA. — Unique analysis of the untreated population examined through a filter of pharmacy benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory—the true local measure of opportunity for pharmaceutical companies. Indications covered in 2010 to include*: — Alzheimer’s disease — Asthma — Attention deficit hyperactivity disorder — Bipolar depression — Chronic obstructive pulmonary disease — Crohn’s disease — Dyslipidemia — Hepatitis C virus — HIV — Hypertension — Major depression — Multiple sclerosis — Parkinson’s disease — Psoriasis — Rheumatoid arthritis — Schizophrenia — Type 2 diabetes (non-insulin) — Ulcerative colitis *Indications subject to change. Why Pharmaceutical Companies Need This Information With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.
